Board Changes & Market Update
20 1월 2009 - 11:19PM
UK Regulatory
TIDMYRK
RNS Number : 9449L
York Pharma plc
20 January 2009
York Pharma plc
("York Pharma" or "the Company")
Board Changes & Market Update
Milton Keynes, UK, 20 January 2009, York Pharma plc (YRK.L), the specialist
dermatology company, provides the following update to its strategic review
announced on 14 January 2009.
To implement its strategic review, York Pharma is making the following changes
to its Board and operational structure with immediate effect.
Terry Sadler, York Pharma's Chief Executive and founder of the business will
move to a new board position as President & Founder. He will focus on strategic
direction and development of the business going forwards.
Richard Anderson (42) has replaced Terry Sadler as Chief Executive Officer. Mr
Anderson has over 20 years experience in the pharmaceutical industry,
principally with Astra Zeneca in a range of UK based and international roles and
latterly as Director of Commercial Planning. Subsequently he went on to be Group
Vice President of Taro Pharmaceuticals Inc. based in New York where he led the
development of their US prescription business and then went on to be Managing
Director of Taro Pharmaceuticals Europe. He was also the founder and CEO of
Derms Development Ltd which he built up through a series of acquisitions before
divesting to York in November 2007.
Ian Miscampbell (47) is appointed as Chief Financial Officer. Mr Miscampbell
qualified as a Chartered Accountant with KPMG in 1987 and spent 8 years with the
firm in the UK and internationally. Subsequently, he has held the position of
Finance Director within the pharmaceutical industry with ReNeuron Limited, KS
Biomedix Holdings Plc, Microscience Holdings Plc, Oxford Immunotec Limited, and
most recently William Ransom & Son Plc. He was also an independent non-executive
director of Synexus Clinical Research plc.
Simon Ainley of Walker Ainley Associates will remain as a consultant to the
Company for a period to ensure an orderly handover of responsibilities to Ian
Miscampbell. Lothar Nau and Michael Garrison will step down from their
respective board positions as Chief Operating Officer and Commercial Director.
The release of the Company's results for the financial year ending 30 September
2008 will now be delayed until 20 March 2009 to allow time for the necessary
adjustments and revaluations arising from the return of Flammazine &
Flammacerium to be properly reflected in the statutory accounts.
Incoming Chief Executive Richard Anderson commented, "We will use recent events
as a positive stimulus to restructure and refocus our business to ensure strong
growth and profitability is achieved and maintained. We are fortunate that the
business has an enviable core asset base and Europe wide sales distribution,
which is delivering performance in line with the Company's expectations. The new
team will simplify the business and focus resources on the establishment of a
sustainable and profitable speciality pharmaceutical business."
Mr Richard James Anderson (aged 42) holds or has held the following
directorships, and is or was a member of the following partnerships during the
past five years:
+--------------------------------------+---+--------------------------------------+
| Current Directorships / | | Past Directorships / Partnerships: |
| Partnerships: | | |
+--------------------------------------+---+--------------------------------------+
| | | |
+--------------------------------------+---+--------------------------------------+
| JJS Pharma (UK) Limited | | Derms Development Limited |
+--------------------------------------+---+--------------------------------------+
| | | |
+--------------------------------------+---+--------------------------------------+
| | | Crawford Healthcare Limited |
+--------------------------------------+---+--------------------------------------+
| | | |
+--------------------------------------+---+--------------------------------------+
| | | Taro (UK) Limited |
+--------------------------------------+---+--------------------------------------+
Mr Anderson is the beneficial owner of 673,000 ordinary shares in the Company.
Mr Ian Alexander Francis Miscampbell (aged 47) holds or has held the following
directorships, and is or was a member of the following partnerships during the
past five years:
+--------------------------------------+---+--------------------------------------+
| Current Directorships / | | Past Directorships / Partnerships: |
| Partnerships: | | |
+--------------------------------------+---+--------------------------------------+
| | | |
+--------------------------------------+---+--------------------------------------+
| None | | William Ransom & Son plc |
+--------------------------------------+---+--------------------------------------+
| | | |
+--------------------------------------+---+--------------------------------------+
| | | Oxford Immunotec Limited |
+--------------------------------------+---+--------------------------------------+
| | | |
+--------------------------------------+---+--------------------------------------+
| | | Synexus Clinical Research plc |
+--------------------------------------+---+--------------------------------------+
| | | |
+--------------------------------------+---+--------------------------------------+
| | | Microscience Holdings plc |
+--------------------------------------+---+--------------------------------------+
Mr Miscampbell does not own any ordinary shares in the Company.
As part of their employment packages, Mr Anderson and Mr Miscampbell will each
be granted one million options vesting in three equal portions over a 3 year
period up to January 2012. The subscription price of these options is 6p, being
the mid market price of York Pharma's shares as at close of market on 19 January
2009.
There are no further disclosures required in respect of Mr Anderson and Mr
Miscampbell under paragraph (g) of Schedule Two of the AIM Rules for Companies.
For more information please contact:
+-----------------------------------------+------------------------------+
| York Pharma plc | Tel: +44 (0) 870 066 4453 |
| Richard Anderson, Chief Executive | |
| Officer | |
+-----------------------------------------+------------------------------+
| | |
+-----------------------------------------+------------------------------+
| Collins Stewart Europe Limited | Tel: +44 (0) 207 523 8350 |
| Hugh Field | |
+-----------------------------------------+------------------------------+
| | |
+-----------------------------------------+------------------------------+
| FinnCap | Tel: +44 (0) 207 600 1658 |
| Geoff Nash | |
+-----------------------------------------+------------------------------+
| | |
+-----------------------------------------+------------------------------+
| Financial Dynamics | Tel: +44 (0) 207 831 3113 |
| David Yates / Ben Brewerton / Emma | |
| Thompson | |
+-----------------------------------------+------------------------------+
About York Pharma PLC
YORK PHARMA PLC is a pharmaceutical Group, established in 2003, which develops,
markets and supplies branded dermatological products to pharmaceutical
wholesalers, hospitals and general practitioners within the field of
dermatology.
The Group currently has at its disposal more than 20 patent families (with over
100 individual patents/patent applications) and intellectual property in
relation to its portfolio of novel dermatology products and technology platforms
in the key therapeutic areas of fungal infection, eczema/dermatitis, psoriasis,
vitiligo and acne that make up more than 87% of the global $10bn dermatology
market. For more information, visit www.yorkpharma.com.
- end -
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAILFLSLDIIFIA
York Pharma (LSE:YRK)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
York Pharma (LSE:YRK)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024
York Pharma (런던증권거래소)의 실시간 뉴스: 최근 기사 0
More York Pharma plc News Articles